2003Unpublished venueRequires access

Vesicular Phospholipid Gels

Martin Brandl, Ulrich Massing

Open publisher page 7 citations

Abstract

Abstract This chapter discusses some of the common limitations with small liposomes as drug carriers and how vesicular phospholipid gels can be used to circumvent them. The purpose of an intravenously injected liposomal drug carrier usually is to circulate in the bloodstream and carry the drug to the desired target organ or tissue. Under ideal circumstances the pharmacokinetics and biodistribution of the carrier-associated drug is merely dependent on the characteristics of the liposomes, not on the drug itself. Size and surface characteristics of the liposomes primarily determine the degree to which they are eliminated from the bloodstream by macrophages and end up in the RES organs spleen and liver (1, 2). Big liposomes (>200 nm) are rapidly eliminated, thus they are inappropriate for i.v. drug delivery. Smaller liposomes are more likely to escape the RES and may thus circulate long enough to reach targets within or nearby the vasculary bed (2). Smaller liposomes furthermore are more likely to extravasate.

About this research paper

What this paper is about

Abstract This chapter discusses some of the common limitations with small liposomes as drug carriers and how vesicular phospholipid gels can be used to circumvent them. The purpose of an intravenously injected liposomal drug carrier usually is to circulate in the bloodstream and carry the drug to the desired target organ or tissue. Under ideal circumstances the pharmacokinetics and biodistribution of the carrier-associated drug is merely dependent on the characteristics of the liposomes, not on the drug itself. Size and surface characteristics of the liposomes primarily determine the degree to which they are eliminated from the bloodstream by macrophages and end up in the RES organs spleen and liver (1, 2). Big liposomes (>200 nm) are rapidly eliminated, thus they are inappropriate for i.v. drug delivery. Smaller liposomes are more likely to escape the RES and may thus circulate long enough to reach targets within or nearby the vasculary bed (2). Smaller liposomes furthermore are more likely to extravasate.

Why it matters

OpenAlex reports 7 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Abstract This chapter discusses some of the common limitations with small liposomes as drug carriers and how vesicular phospholipid gels can be used to circumvent them. The purpose of an intravenously injected liposomal drug carrier usually is to circulate in the bloodstream and carry the drug to the desired target organ or tissue. Under ideal circumstances the pharmacokinetics and biodistribution of the carrier-associated drug is merely dependent on the characteristics of the liposomes, not on the drug itself. Size and surface characteristics of the liposomes primarily determine the degree to which they are eliminated from the bloodstream by macrophages and end up in the RES organs spleen and liver (1, 2). Big liposomes (>200 nm) are rapidly eliminated, thus they are inappropriate for i.v. drug delivery. Smaller liposomes are more likely to escape the RES and may thus circulate long enough to reach targets within or nearby the vasculary bed (2). Smaller liposomes furthermore are more likely to extravasate.

Key concepts: Liposome, Biodistribution, Drug, Phospholipid, Pharmacokinetics, Drug carrier, Spleen, Drug delivery

Related papers

Back to paper searchBrowse research topicsOriginal source
Vesicular Phospholipid Gels — Research Paper | ScholarLens